El Mansoura 1

Researchers are evaluating three different impression techniques for making 3D-printed mandibular implant overdentures in patients who have lost all their lower teeth. This randomized crossover trial involves sixteen patients aged 45 to 70 years who will receive two implants in the lower jaw. The study aims to compare how these techniques influence chewing efficiency and patient satisfaction. The three impression methods being studied are conventional open-tray implant-level impression, functionally generated reline impression, and mucostatic base with functional borders impression. Each participant will wear three different overdentures made using these techniques, each for three months. Between each overdenture period, there is a two-week washout phase during which a provisional denture is worn. The order of techniques is randomly assigned for each patient. Participants will undergo assessments at 3, 6, and 9 months after overdenture insertion. Chewing efficiency will be measured using a color-mixing ability test, and patient satisfaction will be recorded using a Visual Analog Scale. The study includes clinical evaluations and questionnaires to monitor the effects of each impression technique on both function and patient experience.

Diffuse large B-cell lymphoma DLBCL is the most common and aggressive subtype of non-Hodgkin lymphoma, with rapid tumor growth and symptoms varying by tumor location. The disease is classified using advanced methods like immunohistochemistry and molecular testing to guide prognosis and personalized treatment. Despite standard immunochemotherapy curing 60-70% of patients, many experience treatment failure or relapse, and options after second-line therapies remain limited. This observational study examines treatment patterns, demographic, and clinical characteristics of DLBCL patients in the Middle East and Africa. It includes two patient groups those newly diagnosed and eligible for treatment, and those with relapsed or refractory DLBCL who have failed previous therapies. The study aims to explore access to novel therapies and understand real-world treatment approaches in these regions. Participants will be observed over 22 months, during which researchers will document treatment regimens, patient risk profiles, and access to new treatments. Data collection includes patient demographics, disease characteristics, and treatment outcomes. The study does not involve experimental treatments but gathers detailed information to inform future care strategies for DLBCL patients.

Researchers are evaluating the combination of baxdrostat and dapagliflozin in people with chronic kidney disease CKD and high blood pressure hypertension. This Phase III, double-blind, placebo-controlled study aims to assess whether this combination reduces the risk of serious kidney damage, heart failure events, or cardiovascular death compared to dapagliflozin alone. The study includes participants with CKD and hypertension who meet specific kidney function and blood pressure criteria. Participants who are not already taking SGLT2 inhibitors will first complete a 4-week dapagliflozin run-in period. Then, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or a placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur at 2, 4, 8, 16, 34, and 52 weeks after randomization, and then approximately every four months until the study ends, which is based on the number of key kidney or heart-related events. Throughout the study, participants will have regular assessments including blood tests to monitor kidney function and potassium levels, blood pressure measurements, and evaluations of heart and kidney health. If participants stop the blinded study drug early, they will continue dapagliflozin if possible and remain in the study for ongoing visits and monitoring. The main outcome is whether the combination treatment reduces the risk of a 50% sustained decline in kidney function, kidney failure, heart failure events, or cardiovascular death over up to 37 months.

Researchers are evaluating the safety and preliminary effectiveness of oral roflumilast in adults with moderate-to-severe plaque psoriasis in this 12-week pilot study. The study focuses on measuring changes in psoriasis severity using the Psoriasis Area and Severity Index PASI score and includes monitoring changes in body mass index BMI. Both male and female participants will be included and analyzed as subgroups to better understand treatment effects. All participants will receive oral roflumilast starting at 250 mcg once daily for the first 10 days, followed by an increased dose of 500 mcg once daily for the remaining weeks, totaling 12 weeks of treatment. There is no placebo or comparison group. The study is open-label and single-arm, meaning all participants know they receive the active drug. Participants will undergo detailed medical history reviews and clinical exams before starting treatment. During the 12 weeks, they will attend scheduled visits for assessments of psoriasis severity, BMI, and safety monitoring including adverse events and laboratory tests. Data will be collected and analyzed overall and by sex-based subgroups to evaluate treatment effects and safety.

Researchers are evaluating intra-lesional immunotherapy using the measles-mumps-rubella MMR vaccine as a treatment for recalcitrant tinea cruris and corporis. This condition involves persistent fungal infections that have not improved with standard antifungal treatments. The study targets patients aged 10 to 60 years who have experienced rapid progression, large affected skin areas, infections in multiple family members, rapid relapse, or suspected resistant strains of the fungus. The purpose is to assess the safety and therapeutic effect of this novel immunotherapy in a pilot setting. Participants will receive injections of the MMR vaccine directly into the active borders of their fungal lesions every two weeks for six weeks. If there is partial improvement but not full clearance after the initial treatment, the course may be extended for an additional six weeks, with up to six injection sessions total. In addition, patients will take pulse itraconazole during the first two weeks of the study. All participants receive the same treatment without a comparison or placebo group. Throughout the study, clinicians will monitor skin involvement and symptoms such as itching at each visit every two weeks, up to 6 weeks, with possible extension to 12 weeks if treatment continues. Safety assessments will track injection site reactions, fevers, lesion flares, and any rare serious allergic effects. The main outcome will be the percent reduction in the affected body surface area. Safety and tolerance of the injections will be observed continuously during treatment and extension periods. Participants are expected to be involved for up to 12 weeks in total.

Researchers are evaluating three different techniques for making impressions to create full-arch implant-supported dental prostheses. This study focuses on participants who have four well-integrated dental implants in the lower jaw. The goal is to compare conventional splinted impressions, standard digital scanning, and geometric pattern-assisted digital scanning to see which method provides the most accurate fit for the final prosthetic framework, which is important for implant success and patient comfort. Participants will experience all three impression methods in a randomized order. The conventional method uses splinted impression copings and polyvinyl siloxane PVS material on a custom tray. The standard digital scan uses an intraoral scanner with scan bodies attached to the implants. The geometric pattern-assisted digital scan adds a visual reference pattern to the digital scanning process to improve accuracy. Each impression produces a digital model, and prosthetic frameworks are made using CADCAM technology and 3D laser sintering. During the study, the accuracy of each impression technique is assessed by measuring the three-dimensional deviation between test and reference scans immediately after each impression. Clinical fit is also evaluated using a one-screw test within one hour of framework placement. Participants will attend all required appointments and provide feedback. The study will monitor the precision of these methods to help improve digital prosthodontic workflows and outcomes. Total participation spans the time needed to complete all three impression sessions and evaluations.

This research aims to evaluate the use of activated charcoal in managing hyperphosphatemia, a condition common in patients with end-stage renal disease ESRD who are on dialysis. Hyperphosphatemia can contribute to worsening vascular calcification, and current management mainly involves limiting dietary phosphorus and using phosphate binders. Activated charcoal, which is generally well tolerated, is being studied as a possible alternative to conventional phosphate binders in dialysis patients. Participants are randomly assigned to one of two groups one group receives standard care with calcium-based or non-calcium based phosphate binders such as sevelamer, while the other group receives these standard binders plus oral activated charcoal capsules taken with meals. The study is double-blinded and conducted over 8 weeks to assess the effect of activated charcoal on mineral and bone disorder related to chronic kidney disease. During the study, participants will have their serum phosphorus levels measured to evaluate treatment effects. Researchers will also track the percentage of patients who experience a significant decrease in itching intensity using a numerical rating scale. The study includes safety monitoring and aims to gather data on both efficacy and side effects. Overall participation duration includes screening, treatment, and follow-up during the 8-week trial period.

Researchers are studying inflammatory bowel diseases IBD, which include Crohns disease and ulcerative colitis UC. These complex, recurring conditions cause symptoms like severe diarrhea, abdominal pain, weight loss, and fatigue, sometimes leading to serious complications. The study aims to evaluate the effects of dapagliflozin combined with mesalamine on IBD by focusing on how activating autophagy and suppressing cell death may reduce disease activity. Participants will be randomly assigned to one of two groups for six months. One group will receive mesalamine alone, taken as 1 gram three times daily. The other group will take the same mesalamine dose plus dapagliflozin 10 mg once daily. Both treatments are drugs being studied to assess their impact on IBD symptoms and inflammation. During the study, researchers will monitor participants over six months, measuring changes in the Mayo score, a tool used to assess UC severity. Participants will have regular evaluations to track symptoms and disease progression. The study is double-blinded, meaning neither the participants nor the researchers know who is receiving which treatment, to ensure unbiased results. This trial is designed for adults aged 18 to 60 with mild to moderate ulcerative colitis.

Researchers are evaluating the effectiveness of acupuncture and transcutaneous electrical nerve stimulation TENS as physical therapy approaches to reduce pain following upper abdominal surgeries, such as laparoscopic cholecystectomy and gastrectomy. This study aims to compare the safety and pain-reducing benefits of these two methods to provide guidance for postoperative pain management. Participants will be randomly assigned to one of two groups one will receive acupuncture treatment three times a week for four weeks alongside standard medical care, and the other will receive TENS therapy with the same frequency and duration plus medical treatment. Acupuncture involves needle insertion at specific points with manipulation to induce sensations like soreness or numbness, starting within two hours after surgery and continuing daily for gastrectomy patients. TENS treatment uses a device providing electrical stimulation for up to 48 hours post-surgery, with patients adjusting intensity for pain relief. During the study, participants recovery quality and pressure pain threshold will be measured at the start and after four weeks. Assessments include monitoring pain levels, physical therapy effects, and safety. The total participation period spans four weeks, with ongoing evaluations to determine changes in postoperative pain and recovery.

Researchers are comparing the effects of two medications, dapagliflozin and acetazolamide, in adults hospitalized with acute heart failure who show signs of fluid overload. This study aims to see which drug better improves fluid removal and breathing difficulty, as well as shortens hospital stays. Both drugs will be given alongside standard loop diuretic therapy, and their safety will be monitored to detect any side effects. The goal is to gather evidence that could help improve treatment for acute heart failure. Participants will be randomly assigned to receive either dapagliflozin 10 mg once daily or acetazolamide 500 mg once daily, both taken by mouth in addition to their usual loop diuretics and care for three days. This is a double-blind study, so neither the participants nor the researchers will know which treatment is given. The study begins shortly after hospital admission and treatments are given during the initial days of hospitalization. During the study, participants will be monitored closely for changes in their breathing difficulty using a visual scale from baseline to day three. Other health assessments and safety checks will be completed to track responses and any side effects. The overall hospital stay length and kidney function will also be observed. The total participation time covers the initial hospitalization period and follow-up assessments as scheduled by the study team.